Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

PURPOSE: Non-alcoholic fatty liver disease (NAFLD) affects about 75% of patients with type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to determine the effect of canagliflozin on fatty liver indexes in T2DM patients. METHODS: A literature search of PubMed, Embase and Cochrane was condu...

Full description

Bibliographic Details
Main Authors:	Boyu Li, Ying Wang, Zhikang Ye, Hui Yang, Xiangli Cui, Zhenjun Wang, Lihong Liu
Format:	Article
Language:	English
Published:	Canadian Society for Pharmaceutical Sciences 2018-06-01
Series:	Journal of Pharmacy & Pharmaceutical Sciences
Online Access:	https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/29831

Similar Items

Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
by: Lei Tian, et al.
Published: (2021-07-01)

Antidepressant Use and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis
by: Ying Wang, et al.
Published: (2019-01-01)

Canagliflozin-Induced Diabetic Ketoacidosis
by: Jessica Turner MSIV, et al.
Published: (2016-08-01)

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
by: Atsushi Tanaka, et al.
Published: (2020-08-01)

Prolonged diabetic ketoacidosis associated with canagliflozin
by: Gordon Sloan, et al.
Published: (2018-06-01)

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats
by: Takahiro Oguma, et al.
Published: (2015-04-01)

Patient profiling in diabetes and role of canagliflozin
by: Amblee A
Published: (2014-11-01)

Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease
by: Mitsuko Inoue, et al.
Published: (2019-07-01)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
by: Syed Raza Shah, et al.
Published: (2018-09-01)

Effectiveness of Pharmacist-led Anticoagulation Management on Clinical Outcomes: A Systematic Review and Meta-Analysis
by: Kelu Hou, et al.
Published: (2018-01-01)

Canagliflozin and risk of amputation in patients with type 2 diabetes
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
by: Curtis Triplitt, et al.
Published: (2015-10-01)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
by: Curtis Triplitt, et al.
Published: (2015-01-01)

Emerging treatments in type 2 diabetes: focus on canagliflozin
by: Rosiak M, et al.
Published: (2014-08-01)

Canagliflozin - Beginning of the journey
by: Sunil Kumar Pandey, et al.
Published: (2014-01-01)

Diabetic Ketoacidosis in A Patient with Type 2 Diabetes On Canagliflozin and Dexamethasone
by: Lisa D. Alexander, MD, et al.
Published: (2017-01-01)

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
by: Shu-ting Wang, et al.
Published: (2020-03-01)

Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report
by: Masafumi Fukuda, et al.
Published: (2020-01-01)

Canagliflozin: a novel treatment option for type 2 diabetes
by: Dietrich E, et al.
Published: (2013-11-01)

Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis
by: Kirandeep Kaur, et al.
Published: (2015-01-01)

Crystal structure of canagliflozin hemihydrate
by: Kai-Hang Liu, et al.
Published: (2016-05-01)

Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials
by: Pravesh Kumar Bundhun, et al.
Published: (2017-04-01)

A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
by: AnneMarie Nardolillo, et al.
Published: (2014-01-01)

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
by: Akira Sezai, et al.
Published: (2019-06-01)

A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
by: AnneMarie Nardolillo, et al.
Published: (2014-09-01)

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
by: Shusuke Yagi, et al.
Published: (2017-10-01)

Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
by: Takahara M, et al.
Published: (2020-11-01)

Evaluating the efficacy of Salsalate on prediabetic and diabetic patients with fatty liver: A randomized clinical trial
by: Elham Faghihimani, et al.
Published: (2013-01-01)

Clinical Outcomes with Antiviral Prophylaxis or Preemptive Therapy for Cytomegalovirus Disease after Liver Transplantation: A Systematic Review and Meta-Analysis
by: yang hui, et al.
Published: (2017-01-01)

Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
by: Xi-Xi He, et al.
Published: (2016-01-01)

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
by: Daisuke Matsutani, et al.
Published: (2018-05-01)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014-01-01)

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
by: Ven G. Lim, MBChB, et al.
Published: (2019-02-01)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India
by: K M Prasanna Kumar, et al.
Published: (2016-01-01)

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes
by: Skelley JW, et al.
Published: (2018-12-01)

Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis
by: Marco Castellana, et al.
Published: (2021-04-01)

Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
by: Qiong Wei, et al.
Published: (2021-06-01)

The effects of omega-3 fatty acids on diabetic nephropathy: A meta-analysis of randomized controlled trials.
by: Api Chewcharat, et al.
Published: (2020-01-01)

EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
by: Rishad Ahmed, et al.
Published: (2017-01-01)

Efficacy and safety of canagliflozin in kidney transplant patients
by: Mita Shah, et al.
Published: (2019-01-01)